Disentangling molecular and clinical stratification patterns in beta-galactosidase deficiency

Introduction This study aims to define the phenotypic and molecular spectrum of the two clinical forms of β-galactosidase (β-GAL) deficiency, GM1-gangliosidosis and mucopolysaccharidosis IVB (Morquio disease type B, MPSIVB). Methods Clinical and genetic data of 52 probands, 47 patients with GM1-gangliosidosis and 5 patients with MPSIVB were analysed. Results The clinical presentations in patients with GM1-gangliosidosis are consistent with a phenotypic continuum ranging from a severe antenatal form with hydrops fetalis to an adult form with an extrapyramidal syndrome. Molecular studies evidenced 47 variants located throughout the sequence of the GLB1 gene, in all exons except 7, 11 and 12. Eighteen novel variants (15 substitutions and 3 deletions) were identified. Several variants were linked specifically to early-onset GM1-gangliosidosis, late-onset GM1-gangliosidosis or MPSIVB phenotypes. This integrative molecular and clinical stratification suggests a variant-driven patient assignment to a given clinical and severity group. Conclusion This study reports one of the largest series of b-GAL deficiency with an integrative patient stratification combining molecular and clinical features. This work contributes to expand the community knowledge regarding the molecular and clinical landscapes of b-GAL deficiency for a better patient management.

[1]  S. Diederich,et al.  The Clinical and Molecular Spectrum of GM1 Gangliosidosis. , 2019, The Journal of pediatrics.

[2]  C. Kim,et al.  Clinical findings in Brazilian patients with adult GM1 gangliosidosis , 2019, JIMD reports.

[3]  Yuyu Feng,et al.  Clinical and molecular characteristics of 11 Chinese probands with GM1 gangliosidosis , 2018, Metabolic Brain Disease.

[4]  F. Lamari,et al.  Metabolic causes of nonimmune hydrops fetalis: A next-generation sequencing panel as a first-line investigation. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[5]  Murim Choi,et al.  Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis , 2018, Brain and Development.

[6]  S. Sonnino,et al.  GM1 Ganglioside: Past Studies and Future Potential , 2016, Molecular Neurobiology.

[7]  M. Kabra,et al.  Recurrent and novel GLB1 mutations in India. , 2015, Gene.

[8]  E. Bertini,et al.  GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. , 2011, Biochimica et biophysica acta.

[9]  F. Tsai,et al.  Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity , 2010, Journal of Biomedical Science.

[10]  U. Ramaswami,et al.  GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid β‐galactosidase , 2009, Human mutation.

[11]  Nicola Brunetti-Pierri,et al.  GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. , 2008, Molecular genetics and metabolism.

[12]  Y. Agid,et al.  Movement disorders and inborn errors of metabolism in adults: A diagnostic approach , 2008, Journal of Inherited Metabolic Disease.

[13]  M. Filocamo,et al.  GM1 gangliosidosis: molecular analysis of nine patients and development of an RT‐PCR assay for GLB1 gene expression profiling , 2007, Human mutation.

[14]  D. Grinberg,et al.  Twenty‐one novel mutations in the GLB1 gene identified in a large group of GM1‐gangliosidosis and Morquio B patients: possible common origin for the prevalent p.R59H mutation among gypsies , 2006, Human mutation.

[15]  U. Muthane,et al.  Clinical features of adult GM1 gangliosidosis: Report of three Indian patients and review of 40 cases , 2004, Movement disorders : official journal of the Movement Disorder Society.

[16]  A. Drousiotou,et al.  Four novel mutations in patients from the Middle East with the infantile form of GM1‐gangliosidosis , 2004, Human mutation.

[17]  F. Platt,et al.  Storage diseases: new insights into sphingolipid functions. , 2003, Trends in cell biology.

[18]  J. Cunningham,et al.  Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient , 2003, Human Genetics.

[19]  S. Zhang,et al.  Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase. , 2000, American journal of human genetics.

[20]  E. Zammarchi,et al.  β‐galactosidase gene mutations affecting the lysosomal enzyme and the elastin‐binding protein in GM1‐gangliosidosis patients with cardiac involvement , 2000, Human mutation.

[21]  J. Callahan.  Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein. , 1999, Biochimica et biophysica acta.

[22]  D. Wenger,et al.  Mutations in the lysosomal beta-galactosidase gene that cause the adult form of GM1 gangliosidosis. , 1994, American journal of human genetics.

[23]  N. Nardocci,et al.  Chronic GM1 Gangliosidosis Presenting as Dystonia: Clinical and Biochemical Studies in a New Case , 1993, Neuropediatrics.

[24]  Yoshiyuki Suzuki,et al.  GM1 gangliosidosis in adults: Clinical and molecular analysis of 16 Japanese patients , 1992, Annals of neurology.

[25]  A. Oshima,et al.  Human beta-galactosidase gene mutations in morquio B disease. , 1991, American journal of human genetics.

[26]  E. Nanba,et al.  GM1-gangliosidosis (genetic beta-galactosidase deficiency): identification of four mutations in different clinical phenotypes among Japanese patients. , 1991, American journal of human genetics.

[27]  N. Yanagisawa,et al.  Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases. , 1991, American journal of human genetics.

[28]  R. Giugliani,et al.  GM1 gangliosidosis: Clinical and laboratory findings in eight families , 2004, Human Genetics.

[29]  T. Wight,et al.  Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. , 2004, The American journal of pathology.

[30]  Yoshiyuki Suzuki,et al.  BETA -GALACTOSIDOSIS (GENETIC BETA -GALACTOSIDASE DEFICIENCY) : CLINICAL END GENETIC HETEROGENEITY OF THE SKELETAL FORM , 1995 .